Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis
Etanercept showed no clear difference in proportion of participants cleared or almost cleared in the short… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Percentage of participants reaching PASI 75 · people with paediatric psoriasis
Etanercept leads to higher PASI 75 Participants achieving a 75% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review
PASI 50 · people with paediatric psoriasis
Etanercept leads to higher PASI 50 Participants achieving a 50% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review
PASI 90 · people with paediatric psoriasis
Etanercept leads to higher PASI 90 Participants achieving a 90% improvement in the Psoriasis… compared with placebo (high certainty).
1 finding from 1 review
PGA Participants achieving a PGA of 'clear' or 'almost clear' · people with paediatric psoriasis
Etanercept leads to higher PGA Participants achieving a PGA of 'clear' or 'almost clear' compared with placebo (high certainty).
1 finding from 1 review
CDLQI Scores range from 0 to 30. Lower scores indicate better health‐related quality of life. Calculations are based on the change from baseline to week 12 in both groups · people with paediatric psoriasis
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · participants with hidradenitis suppurativa
1 finding from 1 review
Etanercept · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher etanercept compared with placebo (moderate certainty).
2 findings from 1 review